Development of a protein-based system for transient epigenetic repression of immune checkpoint molecule and enhancement of antitumour activity of natural killer cells.

Published on Jan 21, 2020in British Journal of Cancer5.416
路 DOI :10.1038/s41416-019-0708-y
Yoichi Teratake , Tomoki Takashina1
Estimated H-index: 1
+ 3 AuthorsYukihito Ishizaka30
Estimated H-index: 30
Immune checkpoint blockade (ICB) therapy improved the prognosis of cancer patients, but general administration of ICBs occasionally induces side effects that include immune-related adverse events and tumour hyper-progression. Here, we established a protein-based system, by which endogenous expression of IC molecule in natural killer (NK) cells was transiently repressed on enhancement of their antitumour activity. A protein-based genome modulator (GM) system is composed of a transcription activator-like effector (TALE), DNA methyltransferase and a newly identified potent cell-penetrating peptide with nuclear-trafficking property named NTP. TALE was designed to target the promoter region of the programmed cell death-1 (PD-1) gene. After culturing human NK cells in the presence of NTP-GM protein, we examined endogenous PD-1 expression and antitumour activity of the treated cells. NTP-GM protein efficiently downregulated PD-1 expression in NK cells with increased CpG DNA methylation in the promoter region. The antitumour activity of the treated NK cells was enhanced, and repeated intraperitoneal administrations of the treated NK cells attenuated tumour growth of programmed death-ligand 1-positive tumour cells in vivo. Because the incorporated NTP-GM protein was quickly degraded and negligible in the administered NK cells, the NTP-GM system could be an alternative option of an ICB without side effects.
  • References (34)
  • Citations (0)
馃摉 Papers frequently viewed together
8 Authors (Carlos D. Peinado, ..., Jack D. Bui)
2 Citations
6 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Takahiro Kamada (Nagoya University)H-Index: 2
#2Yosuke TogashiH-Index: 20
Last. Hiroyoshi Nishikawa (Nagoya University)H-Index: 32
view all 16 authors...
PD-1 blockade is a cancer immunotherapy effective in various types of cancer. In a fraction of treated patients, however, it causes rapid cancer progression called hyperprogressive disease (HPD). With our observation of HPD in 鈭10% of anti鈥揚D-1 monoclonal antibody (mAb)-treated advanced gastric cancer (GC) patients, we explored how anti鈥揚D-1 mAb caused HPD in these patients and how HPD could be treated and prevented. In the majority of GC patients, tumor-infiltrating FoxP3 high CD45RA 鈭 CD4 + T ...
14 CitationsSource
#1Heather Walker (Dund.: University of Dundee)H-Index: 1
#2Paul Brennan (Dund.: University of Dundee)H-Index: 1
Last. Frank A. Carey (Ninewells Hospital)H-Index: 18
view all 5 authors...
#1Nicolas Veland (University of Texas MD Anderson Cancer Center)H-Index: 4
#2Yue Lu (University of Texas MD Anderson Cancer Center)H-Index: 27
Last. Taiping Chen (University of Texas MD Anderson Cancer Center)H-Index: 25
view all 15 authors...
5 CitationsSource
#1Jeremiah Oyer (UCF: University of Central Florida)H-Index: 6
#2Sarah B. Gitto (UCF: University of Central Florida)H-Index: 4
Last. Alicja J. Copik (UCF: University of Central Florida)H-Index: 8
view all 4 authors...
ABSTRACTAnti-PD-1/anti-PD-L1 therapies have shown success in cancer treatment but responses are limited to ~聽15% of patients with lymphocyte infiltrated, PD-L1 positive tumors. Hence, strategies that increase PD-L1 expression and tumor infiltration should make more patients eligible for PD-1/PD-L1 blockade therapy, thus improving overall outcomes. PD-L1 expression on tumors is induced by IFN纬, a cytokine secreted by NK cells. Therefore, we tested if PM21-particle expanded NK cells (PM21-NK cells...
6 CitationsSource
#1Kristian M. Hargadon (Hampden鈥揝ydney College)H-Index: 8
#2Coleman E. Johnson (Hampden鈥揝ydney College)H-Index: 1
Last. Corey J. Williams (Hampden鈥揝ydney College)H-Index: 1
view all 3 authors...
Abstract Although T lymphocytes have long been appreciated for their role in the immunosurveillance of cancer, it has been the realization that cancer cells may ultimately escape a response from tumor-reactive T cells that has ignited efforts to enhance the efficacy of anti-tumor immune responses. Recent advances in our understanding of T cell immunobiology have been particularly instrumental in informing therapeutic strategies to overcome mechanisms of tumor immune escape, and immune checkpoint...
64 CitationsSource
#1Tomoki TakashinaH-Index: 1
#2Takayoshi KoyamaH-Index: 6
Last. Yukihito IshizakaH-Index: 30
view all 12 authors...
Abstract Cellular reprogramming is a promising technology in regenerative medicine, but most studies have been performed by using expression vectors. For future clinical applications, it is necessary to establish a system in which cell engineering can be manipulated without any risk of damaging the genome. Here, we identified a cell-penetrating peptide composed of 10 amino acids (RIFIHFRIGC) with nuclear trafficking activity and found that it was significantly more potent than a Tat-derived pept...
3 CitationsSource
#1Yanming SunH-Index: 1
#2Zhitao YaoH-Index: 1
Last. Chuntao SunH-Index: 1
view all 8 authors...
1 CitationsSource
#1Qiaohong Wang (SJTU: Shanghai Jiao Tong University)H-Index: 3
#2Jingze Gao (SJTU: Shanghai Jiao Tong University)H-Index: 1
Last. Xia Wu (SJTU: Shanghai Jiao Tong University)H-Index: 3
view all 3 authors...
Abstract Immune checkpoint inhibitors appear to be one of the most promising immunotherapies with significant clinical benefits and durable responses in multiple tumor types. A heterogeneity of responses appears in patients receiving checkpoint blockade, including pseudoprogression where the tumor burden or number of tumor lesions increases initially before decreasing. Another special response observed after checkpoint blockade is hyperprogression, a phenomenon reflecting a very rapid tumor prog...
15 CitationsSource
Cancer immunotherapy has been a great breakthrough, with immune checkpoint inhibitors leading the way. Despite the clinical effectiveness of certain immune checkpoint inhibitors, the overall response rate remains low, and the effectiveness of immunotherapies for many tumors has been disappointing. There is substantial interest in looking for additional immune checkpoint molecules that may act as therapeutic targets for cancer. Recent advances during the last decade have identified several novel ...
23 CitationsSource
#1Shunsuke TeraokaH-Index: 6
#2Daichi FujimotoH-Index: 12
Last. Keisuke TomiiH-Index: 24
view all 14 authors...
Abstract Introduction Retrospective studies have shown immune-related adverse events (irAEs) to be associated with better prognosis. However, no prospective clinical trials have been conducted, and little is known regarding the association between irAEs and the outcome of patients with NSCLC after treatment with immunotherapy. Methods We conducted a prospective cohort study of patients with advanced NSCLC who were treated with nivolumab between January and December 2016. The association between ...
53 CitationsSource
Cited By0